To include your compound in the COVID-19 Resource Center, submit it here.

Gilead gains access to tumor myeloid targets via Pionyr partnership

Each of Gilead’s five cancer deals this year have given it a line to a new immuno-oncology approach

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells.

In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay $275 million up front to acquire 49.9% of Pionyr Immunotherapeutics Inc. and an exclusive option to buy the remainder of the company.

Pionyr CBO Alicia Levey told

Read the full 607 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers